One-pot synthesis of pH-responsive Eudragit-mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease

Show full item record



Permalink

http://hdl.handle.net/10138/335107

Citation

Qu , Z , Wong , K Y , Moniruzzaman , M , Begun , J , Santos , H A , Hasnain , S Z , Kumeria , T , McGuckin , M A & Popat , A 2021 , ' One-pot synthesis of pH-responsive Eudragit-mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease ' , Advanced Therapeutics , vol. 4 , no. 2 , 2000165 . https://doi.org/10.1002/adtp.202000165

Title: One-pot synthesis of pH-responsive Eudragit-mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease
Author: Qu, Zhi; Wong, Kuan Yau; Moniruzzaman, Md.; Begun, Jakob; Santos, Hélder A.; Hasnain, Sumaira Z.; Kumeria, Tushar; McGuckin, Michael A.; Popat, Amirali
Contributor: University of Helsinki, Division of Pharmaceutical Chemistry and Technology
Date: 2021-02
Language: eng
Number of pages: 11
Belongs to series: Advanced Therapeutics
ISSN: 2366-3987
URI: http://hdl.handle.net/10138/335107
Abstract: Oral glucocorticoids are backbones for the acute management of inflammatory bowel disease (IBD). However, the clinical effectiveness of conventional oral dosage forms of glucocorticoids is hindered by their low delivery efficiency and systemic side effects. To overcome this problem, a smart drug delivery system with high loading capacity and colonic release by coating functionalized mesoporous silica nanoparticles (MSNs) with a pH‐responsive polymer Eudragit S100 is proposed. In vitro dissolution tests show that Eudragit‐coated MSNs can limit the burst release of loaded prednisolone and budesonide in the gastric environment with more than 60% of the drugs released only at colonic pH (i.e., pH ≥ 7). In vivo therapeutic efficacy of budesonide‐loaded nanoparticles is tested in a murine model of dextran sodium sulfate‐induced colitis. An oral budesonide dose of 0.2 mg kg−1 nanoparticles with Eudragit coating improves the disease activity index compared to other groups. Interestingly, both coated and uncoated nanoparticles show pathological improvements demonstrated by similar levels of histological colitis score. However, coated nanoparticles significantly decrease mRNA expression of the cytokines (Il‐1β, Il‐17, and Il‐10) particularly in proximal colon, indicating colonic delivery. Overall, this study demonstrates the effectiveness of a simple method to fabricate targeted nanomedicine for the treatment of IBD.
Subject: BUDESONIDE
ENDOPLASMIC-RETICULUM STRESS
Eudragit
INFLAMED COLON
INTERLEUKIN-10
MCM-41
NANOPARTICLES
RELEASE DRUG-DELIVERY
SYSTEM
T-CELLS
TARGETED DELIVERY
ULCERATIVE-COLITIS
colitis
colonic delivery
mesoporous silica
oral drug delivery
317 Pharmacy
318 Medical biotechnology
221 Nano-technology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
adtp.202000165.pdf 2.291Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record